US judge fines Johnson & Johnson $1.1bn for misleading marketing of risperidoneBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2772 (Published 16 April 2012) Cite this as: BMJ 2012;344:e2772
- Janice Hopkins Tanne
- 1New York
Judge Tim Fox of the Arkansas Circuit Court fined the Johnson & Johnson subsidiary Janssen Pharmaceuticals $1.1bn (£0.7bn; €0.84bn) for promotional information about the antipsychotic drug risperidone that misled the state into spending Medicaid funds for the drug. He also fined the company $11m for violating the state’s law on deceptive practices. Medicaid is a joint federal and state health insurance scheme for people on low incomes.
The Arkansas attorney general, Dustin McDaniel, charged that Johnson & Johnson and Janssen had not clearly described the risks of risperidone (which is marketed as Risperdal), had marketed the drug for unapproved uses, …
Log in using your username and password
Log in through your institution
Sign up for a free trial